Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.

Background: The economic burden associated with irritable bowel syndrome with diarrhea (IBS-D) is not well understood.

Objectives: To (a) evaluate total annual all-cause, gastrointestinal (GI)-related, and symptom-related (i.e.

Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.

Aims: To assess healthcare resource use and costs among irritable bowel syndrome (IBS) with diarrhea (IBS-D) patients with and without evidence of inadequate symptom control on current prescription therapies and estimate incremental all-cause costs associated with inadequate symptom control.

Methods: IBS-D patients aged ≥18 years with ≥1 medical claim for IBS (ICD-9-CM 564.1x) and either ≥2 claims for diarrhea (ICD-9-CM 787.